Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study
Open Access
Abstract
Aim of the study: To compare the course of severity of cervical dystonia (CD) before and after long-term botulinum toxin (BoNT) therapy to detect indicators for a good or poor clinical outcome. Patients and Methods: A total of 74 outpatients with idiopathic CD who were continuously treated with BoNT and who had received at least three injections were consecutively recruited. Patients had to draw the course of severity of CD from the onset of symptoms until the onset of BoNT therapy (CoDB graph), and from the onset of BoNT therapy until the day of recruitment (CoDA graph) when they received their last BoNT injection. Mean duration of treatment was 9.6 years. Three main types of CoDB and four main types of CoDA graphs could be distinguished. The demographic and treatment-related data of the patients were extracted from the patients’ charts. Results: The best outcome was observed in those patients who had experienced a clear, rapid response in the beginning. These patients had been treated with the lowest doses and with a low number of BoNT preparation switches. The worst outcome was observed in those 17 patients who had drawn a good initial improvement, followed by a secondary worsening. These secondary nonresponders had been treated with the highest initial and actual doses and with frequent BoNT preparation switches. A total of 12 patients were primary nonresponders and did not experience any improvement at all. No relation between the CoDB and CoDA graphs could be detected. Primary and secondary nonresponses were observed for all three CoDB types. The use of initial high doses as a relevant risk factor for the later development of a secondary nonresponse was confirmed. Conclusions: Patients’ drawings of their course of disease severity helps to easily detect “difficult to treat” primary and secondary nonresponders to BoNT on the one hand, but also to detect “golden responders” on the other hand.Keywords
Funding Information
- Inge Diesbach-Stiftung
This publication has 46 references indexed in Scilit:
- An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport)BMJ Open, 2013
- Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins—a single cohort 4-year follow-up studyBMJ Open, 2012
- Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian AmericansAutoimmunity, 2010
- HLA-B62 and HLA-DQ8 are associated with Complex Regional Pain Syndrome with fixed dystoniaPain, 2009
- Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type AClinical Neuropharmacology, 2009
- Reliability of the Burke‐Fahn‐Marsden scale in a multicenter trial for dystoniaMovement Disorders, 2007
- The use of botulinum toxin type‐B in the treatment of patients who have become unresponsive to botulinum toxin type‐A – initial experiencesEuropean Journal of Neurology, 2005
- The course of cervical dystonia and patient satisfaction with long‐term botulinum toxin A treatmentEuropean Journal of Neurology, 2005
- Clinical presentation and management of antibody-induced failure of botulinum toxin therapyMovement Disorders, 2004
- Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type AMovement Disorders, 1993